Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $34

Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $40 to $34.